The Tg rasH2 mouse in cancer hazard identification

Toxicologic Pathology

Volumn 30, Issue 1, 2002, Pages 139-146

  Morton, Daniel ^a   Alden, Carl L ^b   Roth, Arthur J ^a   Usui, Toshimi ^c  

^a PFIZER INC   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

Author keywords

Bioassay; Carcinogenicity; CB6F1 TgN (RasH2); Risk assessment; Rodent; TgHras2; Transgenic

Indexed keywords

RAS PROTEIN;

ANGIOSARCOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; CANCER INCIDENCE; CANCER RISK; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; FEMALE; FOOD AND DRUG ADMINISTRATION; GENETIC MODEL; GENOTOXICITY; HEMANGIOMA; LUNG ADENOMA; LUNG CARCINOMA; MALE; MOUSE; NONHUMAN; ONCOGENE H RAS; PAPILLOMA; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; SIMULATION; SKIN TUMOR; SPLEEN TUMOR; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; STOMACH TUMOR; TRANSGENIC MOUSE; TRANSGENIC RASH2 MOUSE;

ANIMALS; CARCINOGENICITY TESTS; CARCINOGENS; GENES, RAS; MICE; MICE, TRANSGENIC; MUTAGENS; NEOPLASMS; RESEARCH DESIGN;

ANIMALIA; MUS MUSCULUS; RODENTIA;

EID: 0036185655     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/01926230252824851     Document Type: Article

References (22)

1. International Conference on Harmonization; Guidance on testing for carcinogenicity of pharmaceuticals
2. Effects of clofibrate in the CB6F1-TG-RASH2 mouse
3. In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals
4. Results of 6-month oral carcinogenicity study with 17-β-estradiol in transgenic TgHras2 and wild-type mice
5. Interlaboratory comparison of the CB6F1-Tg rasH2 rapid carcinogenicity testing model
6. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies
7. Rapid-carcinogenicity testing of 1,4-dioxane, ethylene thiourea, cholestyramine, and sulfisoxasole using Tg-rasH2 mice
8. Detection of carcinogenic potential of diethylstilbestrol and N-methyl-N-nitrosourea by the alternative testing model using Tg-rasH2 mouse
9. Testing of clofibrate in a six-month gavage study using RasH2 mice
10. Assessment of transgene orientation in the Tg rasH2 transgenic mouse: A critical step in monitoring transgene stability of microinjected animals
11. Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes
12. Molecular biological studies in the rasH2 transgenic mouse
13. 26-Week carcinogenicity study of metaproterenol sulfate in Tg-rasH2 mice
14. Genetically altered mouse models for identifying carcinogens
15. 26-Week carcinogenicity study of sulfamethoxazole in CB6F1-Tg-rasH2 mice
16. Di(2-ethylhexyl) phthalate induces hepatocellular neoplasm in male rasH2 mice in 26-week carcinogenicity study
17. Spontaneous occurring skeletal myopathy in CB6F1-Tg rasH2 mice
18. 26-Week carcinogenicity study of phenobarbital in CB6F1 CB6F1-Tg rasH2 mice and examination of hepatic carcinogenicity of phenobarbital in CB6F1-Tg rasH2 mice initiated with N-diethylnitrosamine
19. Sequential histopathological study on Tg-rasH2 mice after administration of MNU
20. Rapid carcinogenicity testing system with transgenic mice harboring human prototype c-HRAS gene
21. Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harbouring human prototype C-Ha-ras gene than in control nontransgenic mice
22. Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing